Danaher Co. (NYSE:DHR) Shares Sold by Cadence Bank

Cadence Bank cut its holdings in Danaher Co. (NYSE:DHR) by 1.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,788 shares of the conglomerate’s stock after selling 215 shares during the period. Cadence Bank’s holdings in Danaher were worth $3,277,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Ancora Advisors LLC increased its position in shares of Danaher by 4.6% during the first quarter. Ancora Advisors LLC now owns 6,898 shares of the conglomerate’s stock valued at $1,723,000 after acquiring an additional 305 shares during the last quarter. New Covenant Trust Company N.A. purchased a new position in shares of Danaher during the 1st quarter worth approximately $153,000. Heartland Bank & Trust Co raised its position in Danaher by 61.4% in the first quarter. Heartland Bank & Trust Co now owns 2,174 shares of the conglomerate’s stock valued at $543,000 after purchasing an additional 827 shares during the period. Citizens Financial Group Inc. RI boosted its position in shares of Danaher by 3.4% during the first quarter. Citizens Financial Group Inc. RI now owns 7,949 shares of the conglomerate’s stock worth $1,985,000 after buying an additional 263 shares during the period. Finally, Wahed Invest LLC raised its holdings in shares of Danaher by 15.2% in the 1st quarter. Wahed Invest LLC now owns 12,873 shares of the conglomerate’s stock valued at $3,215,000 after buying an additional 1,698 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Price Performance

Shares of DHR opened at $236.53 on Wednesday. The firm has a fifty day moving average price of $256.66 and a 200 day moving average price of $259.81. The stock has a market cap of $170.84 billion, a PE ratio of 45.14, a price-to-earnings-growth ratio of 4.37 and a beta of 0.85. Danaher Co. has a 1-year low of $215.68 and a 1-year high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The business’s revenue was up 3.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.02 EPS. As a group, sell-side analysts anticipate that Danaher Co. will post 7.5 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were given a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.46%. Danaher’s dividend payout ratio (DPR) is 20.61%.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Robert W. Baird lowered their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Evercore ISI lifted their price objective on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. UBS Group reduced their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. KeyCorp upped their price objective on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Finally, Royal Bank of Canada decreased their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $287.16.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.